Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis

PLoS One. 2016 Mar 28;11(3):e0150625. doi: 10.1371/journal.pone.0150625. eCollection 2016.

Abstract

Background: Clevidipine is an ultrashort-acting drug for rapid reduction of blood pressure by selectively acting on the L-type Ca2+ channels on arteriolar smooth muscle. The drug's ultrashort action in reducing the blood pressure is due to its rapid hydrolysis by blood and extravascular tissue esterases, which does not depend on hepato-renal metabolism and excretion. An analysis of the perioperative management of blood pressure should be considered to compare with other intravenous antihypertensive agents.

Methods: Analyses of the available evidence in randomized clinical trials following the PRISMA methodology as well as clinical significance according to the GRADE system were conducted. Placebo versus other antihypertensive drugs studies were included. Statistical assessments were done using the X2 and I2 tests.

Results: Clevidipine was more effective in maintaining the blood pressure within pre-specified ranges compared with other antihypertensive drugs (MD, -17.87 CI 95%: -29.02 to -6.72; p = 0.02). The use of Clevidipine versus placebo and rescue antihypertensive intravenous drug showed a clear reduction in rates of treatment failure (RR 0.10; IC 95%; 0.05-0.18; p <0.0001). There was no difference in the incidence of adverse events compared with placebo (RR 1.47; 95% CI 0.89 to 2.43, p = 0.14) and with other antihypertensive drugs (RR 0.78, 95% CI 0.45 to 1.35; p = 0.37). In addition, there was no difference in the incidence of atrial fibrillation (AF) between clevidipine and control groups (RR 1.09, IC del 95%: 0.65 a 1.83; p = 0.73).

Conclusions: Clevidipine is an ultrafast-acting drug that is highly effective for management of perioperative arterial hypertension. It is devoid of adverse effects associated with the use of other IV antihypertensives. Its favorable pharmacodynamic and pharmacokinetic properties make clevidipine the drug of choice for the management of acute perioperative hypertension. It is important to emphasize the need for further studies with a larger number of patients to confirm these findings and increase the degree of evidence.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use*
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / pathology
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / therapeutic use*
  • Databases, Factual
  • Humans
  • Hypertension / drug therapy*
  • Perioperative Care
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Pyridines
  • clevidipine

Grants and funding

The authors disclose no source of funding for the preparation of this manuscript. The EAR Group (www.eargroup.es) is an international research group within the Department of Pharmacology, Faculty of Medicine of the Complutense University of Madrid (Spain). Collaborative, nonprofit and exempt funding.